Blogs

AZ Shows Off osimertinib setting the groundwork for move into 1L EGFRm+ NSCLC AZ´s symposium presentations focused on promoting the value of 3rd Gen TKIs and liquid biopsies. AZ took the opportunity to emphasize that osimertinib is the only 3rd Gen TKI in the market highlighting the discontinuation of rociletinib and BI´s disengagement with olmutinib. Osimertinib´s positive data in 1L and 2L with/without T790 mutation was shown; the AURA pooled data from n=397 patients shows

Merck carried off the prize in 1st Line NSCLC with KEYNOTE-021G and KEYNOTE-024 data Keytruda showed impressive results in 1L NSCLC both as a monotherapy and in combination with chemo. In the monotherapy study (KEYNOTE-024) focused on high PD-L1 expressors (TPS ≥50%), Keytruda gave superior results versus chemotherapy (mPFS: 10.3 vs 6 mos.). These results led to Keytruda’s approval as a 1L treatment (FDA approval on 24th Oct 2016, 2 months ahead of the original